A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience
CONCLUSIONS: For progressive HR+, HER2- MBC, alpelisib + ET showed effectiveness in a real-world patient population that was comparable to published clinical trial data, regardless of starting dose. However, the effectiveness of alpelisib following previous everolimus exposure may be limited and, hence, should be a consideration to decide sequencing of therapy in these patients. Patients treated with alpelisib are at risk for clinically relevant AEs and require close monitoring.PMID:38011835 | DOI:10.1159/000534953
Source: Oncology - Category: Cancer & Oncology Authors: Humaira Sarfraz Shahla Bari Junmin Whiting Melissa Sur Qianxing Mo Melissa Armitage Ricardo L B Costa Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Endocrine Therapy | HER2 | Hormones | Oral Cancer | Statistics | Study | Toxicology | Women